Global Stem Cell Therapy Market to Reach $605.2 Million by 2027

NEW YORK, Nov. 3, 2022 /PRNewswire/ -- Abstract:

What’s New for 2022?

Global competitiveness and key competitor percentage market shares



Read the full report: https://www.reportlinker.com/p06033005/?utm_source=PRN


Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year

Global Stem Cell Therapy Market to Reach $605.2 Million by 2027

In the changed post COVID-19 business landscape, the global market for Stem Cell Therapy estimated at US$209 Million in the year 2020, is projected to reach a revised size of US$605.2 Million by 2027, growing at aCAGR of 16.4% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 16.9% CAGR and reach US$574.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Autologous segment is readjusted to a revised 9.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $61.1 Million, While China is Forecast to Grow at 15.7% CAGR

The Stem Cell Therapy market in the U.S. is estimated at US$61.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$104.7 Million by the year 2027 trailing a CAGR of 15.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.4% and 13.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.5% CAGR.

Select Competitors (Total 12 Featured) -
Advanced Cell Technology
Anterogen, Ltd.
Biotime, Osiris Therapeutics
Cynata
Cytori Therapeutics
HolostemTerapieAvanzateS.r.l.
Human Longevity
JCR Pharmaceuticals
Medipost
Mesoblastand AlloSource
NuVasive
Osiris Therapeutics, Inc.
Pharmicell
Promethera Biosciences
RTI Surgical
Stemcell Technologies



Read the full report: https://www.reportlinker.com/p06033005/?utm_source=PRN

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Stem Cell Therapy - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Stem
Cell Therapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 2: World Historic Review for Stem Cell Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Stem Cell Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Allogeneic by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Allogeneic by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Allogeneic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Autologous by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Autologous by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Autologous by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Gastrointestinal Diseases by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 11: World Historic Review for Gastrointestinal Diseases
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Gastrointestinal
Diseases by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 14: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Musculoskeletal Disorders by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 17: World Historic Review for Musculoskeletal Disorders
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Musculoskeletal
Disorders by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Wounds & Injuries by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 20: World Historic Review for Wounds & Injuries by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Wounds & Injuries by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Cardiovascular Diseases by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 23: World Historic Review for Cardiovascular Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Cardiovascular Diseases
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 26: World Historic Review for Adipose Tissue-Derived MSCs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Adipose Tissue-Derived
MSCs by Geographic Region - Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for Bone
Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 29: World Historic Review for Bone Marrow-Derived MSCs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Bone Marrow-Derived
MSCs by Geographic Region - Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 31: World Recent Past, Current & Future Analysis for
Other Cell Sources by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 32: World Historic Review for Other Cell Sources by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Other Cell Sources by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 34: World Stem Cell Therapy Market Analysis of Annual
Sales in US$ for Years 2012 through 2027

Table 35: World Recent Past, Current & Future Analysis for
Placental / Umbilical Cord-Derived MSCs by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$ for
Years 2020 through 2027 and % CAGR

Table 36: World Historic Review for Placental / Umbilical
Cord-Derived MSCs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 37: World 15-Year Perspective for Placental / Umbilical
Cord-Derived MSCs by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2022 (E)
Table 38: USA Recent Past, Current & Future Analysis for Stem
Cell Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 39: USA Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 40: USA 15-Year Perspective for Stem Cell Therapy by Type -
Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 41: USA Recent Past, Current & Future Analysis for Stem
Cell Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 42: USA Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 43: USA 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 44: USA Recent Past, Current & Future Analysis for Stem
Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs
and Other Cell Sources - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 45: USA Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Placental / Umbilical Cord-Derived MSCs and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 46: USA 15-Year Perspective for Stem Cell Therapy by Cell
Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

CANADA
Table 47: Canada Recent Past, Current & Future Analysis for
Stem Cell Therapy by Type - Allogeneic and Autologous -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 48: Canada Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 49: Canada 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 50: Canada Recent Past, Current & Future Analysis for
Stem Cell Therapy by Application - Gastrointestinal Diseases,
Other Applications, Musculoskeletal Disorders, Wounds &
Injuries and Cardiovascular Diseases - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 51: Canada Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 52: Canada 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 53: Canada Recent Past, Current & Future Analysis for
Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs,
Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived
MSCs and Other Cell Sources - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 54: Canada Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Placental / Umbilical Cord-Derived MSCs and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 55: Canada 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

JAPAN
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2022 (E)
Table 56: Japan Recent Past, Current & Future Analysis for Stem
Cell Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 57: Japan Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 58: Japan 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 59: Japan Recent Past, Current & Future Analysis for Stem
Cell Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 60: Japan Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 61: Japan 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 62: Japan Recent Past, Current & Future Analysis for Stem
Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs
and Other Cell Sources - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 63: Japan Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Placental / Umbilical Cord-Derived MSCs and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 64: Japan 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

CHINA
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2022 (E)
Table 65: China Recent Past, Current & Future Analysis for Stem
Cell Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 66: China Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 67: China 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 68: China Recent Past, Current & Future Analysis for Stem
Cell Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 69: China Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 70: China 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 71: China Recent Past, Current & Future Analysis for Stem
Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs
and Other Cell Sources - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 72: China Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Placental / Umbilical Cord-Derived MSCs and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 73: China 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

EUROPE
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2022 (E)
Table 74: Europe Recent Past, Current & Future Analysis for
Stem Cell Therapy by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 75: Europe Historic Review for Stem Cell Therapy by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 76: Europe 15-Year Perspective for Stem Cell Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2021 & 2027

Table 77: Europe Recent Past, Current & Future Analysis for
Stem Cell Therapy by Type - Allogeneic and Autologous -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 78: Europe Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 79: Europe 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 80: Europe Recent Past, Current & Future Analysis for
Stem Cell Therapy by Application - Gastrointestinal Diseases,
Other Applications, Musculoskeletal Disorders, Wounds &
Injuries and Cardiovascular Diseases - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 81: Europe Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 82: Europe 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 83: Europe Recent Past, Current & Future Analysis for
Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs,
Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived
MSCs and Other Cell Sources - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 84: Europe Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Placental / Umbilical Cord-Derived MSCs and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 85: Europe 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

FRANCE
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2022 (E)
Table 86: France Recent Past, Current & Future Analysis for
Stem Cell Therapy by Type - Allogeneic and Autologous -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 87: France Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 88: France 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 89: France Recent Past, Current & Future Analysis for
Stem Cell Therapy by Application - Gastrointestinal Diseases,
Other Applications, Musculoskeletal Disorders, Wounds &
Injuries and Cardiovascular Diseases - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 90: France Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 91: France 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 92: France Recent Past, Current & Future Analysis for
Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs,
Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived
MSCs and Other Cell Sources - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 93: France Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Placental / Umbilical Cord-Derived MSCs and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 94: France 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

GERMANY
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2022 (E)
Table 95: Germany Recent Past, Current & Future Analysis for
Stem Cell Therapy by Type - Allogeneic and Autologous -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 96: Germany Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 97: Germany 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 98: Germany Recent Past, Current & Future Analysis for
Stem Cell Therapy by Application - Gastrointestinal Diseases,
Other Applications, Musculoskeletal Disorders, Wounds &
Injuries and Cardiovascular Diseases - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 99: Germany Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 100: Germany 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 101: Germany Recent Past, Current & Future Analysis for
Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs,
Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived
MSCs and Other Cell Sources - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 102: Germany Historic Review for Stem Cell Therapy by
Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived
MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell
Sources Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 103: Germany 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

ITALY
Table 104: Italy Recent Past, Current & Future Analysis for
Stem Cell Therapy by Type - Allogeneic and Autologous -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027 and % CAGR

Table 105: Italy Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 106: Italy 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 107: Italy Recent Past, Current & Future Analysis for
Stem Cell Therapy by Application - Gastrointestinal Diseases,
Other Applications, Musculoskeletal Disorders, Wounds &
Injuries and Cardiovascular Diseases - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 108: Italy Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 109: Italy 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 110: Italy Recent Past, Current & Future Analysis for
Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs,
Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived
MSCs and Other Cell Sources - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 111: Italy Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Placental / Umbilical Cord-Derived MSCs and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 112: Italy 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

UNITED KINGDOM
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United Kingdom for 2022 (E)
Table 113: UK Recent Past, Current & Future Analysis for Stem
Cell Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 114: UK Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 115: UK 15-Year Perspective for Stem Cell Therapy by Type -
Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2021 & 2027

Table 116: UK Recent Past, Current & Future Analysis for Stem
Cell Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 117: UK Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 118: UK 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2021 & 2027

Table 119: UK Recent Past, Current & Future Analysis for Stem
Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs
and Other Cell Sources - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 120: UK Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Placental / Umbilical Cord-Derived MSCs and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 121: UK 15-Year Perspective for Stem Cell Therapy by Cell
Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental /
Umbilical Cord-Derived MSCs and Other Cell Sources for the
Years 2012, 2021 & 2027

REST OF EUROPE
Table 122: Rest of Europe Recent Past, Current & Future
Analysis for Stem Cell Therapy by Type - Allogeneic and
Autologous - Independent Analysis of Annual Sales in US$ for
the Years 2020 through 2027 and % CAGR

Table 123: Rest of Europe Historic Review for Stem Cell Therapy
by Type - Allogeneic and Autologous Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 124: Rest of Europe 15-Year Perspective for Stem Cell

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033005/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker